Department of Orthopedic Surgery, Chonnam National University Medical School and Hospital, 42 Jebongro, Donggu, Gwangju, 61469, Republic of Korea.
J Orthop Surg Res. 2020 Jun 5;15(1):207. doi: 10.1186/s13018-020-01731-5.
Total ankle arthroplasty has progressed as a treatment option for patients with ankle osteoarthritis. However, no studies have been conducted to evaluate the effect of gender on the outcome. The purpose of the present study was to evaluate outcomes, survivorship, and complications rates of total ankle arthroplasty, according to gender differences.
This study included 187 patients (195 ankles) that underwent mobile-bearing HINTEGRA prosthesis at a mean follow-up of 7.5 years (range, 4 to 14). The two groups consisted of a men's group (106 patients, 109 ankles) and a women's group (81 patients, 86 ankles). Average age was 64.4 years (range, 45 to 83).
Clinical scores on the Ankle Osteoarthritis Scale for pain and disability, and American Orthopaedic Foot and Ankle Society ankle-hindfoot score improved and the difference was not statistically significant between the two groups at the final follow-up. There were no significant differences in complication rates and implant survivorship between the two groups. The overall survival rate was 96.4% in men and 93.4% in women at a mean follow-up of 7.5 years (p = 0.621).
Clinical outcomes, complication rates, and survivorship of total ankle arthroplasty were comparable between men and women. These results suggest that gender did not seem to affect outcomes of total ankle arthroplasty in patients with ankle osteoarthritis.
Therapeutic level III.
全踝关节置换术已成为治疗踝关节骨关节炎患者的一种选择。然而,目前还没有研究评估性别对手术结果的影响。本研究旨在根据性别差异评估全踝关节置换术的结果、生存率和并发症发生率。
本研究纳入了 187 例(195 踝)接受可活动衬垫 HINTEGRA 假体的患者,平均随访 7.5 年(4 至 14 年)。两组患者包括男性组(106 例,109 踝)和女性组(81 例,86 踝)。平均年龄为 64.4 岁(45 至 83 岁)。
踝关节骨关节炎量表的疼痛和残疾评分以及美国矫形足踝协会踝后足评分在临床评分方面均有所改善,且两组在最终随访时差异无统计学意义。两组的并发症发生率和植入物生存率无显著差异。男性的总体生存率为 96.4%,女性为 93.4%,平均随访 7.5 年(p = 0.621)。
全踝关节置换术的临床结果、并发症发生率和生存率在男性和女性之间相当。这些结果表明,性别似乎不会影响踝关节骨关节炎患者全踝关节置换术的结果。
治疗水平 III。